Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Peringkat dalam Saham
#3418
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Harga Saham
$4.48
Kapitalisasi Pasar
$4.99B
Perubahan (1 hari)
-5.20%
Perubahan (1 tahun)
-41.89%
Negara
CN
Perdagangan Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Kategori
Healthcare
Rasio P/E untuk Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Rasio P/E per October 2026 TTM: 49.54
Menurut laporan keuangan dan harga saham terbaru dari Shenzhen Salubris Pharmaceuticals Co., Ltd., rasio P/E saat ini (TTM) adalah 49.54. Pada akhir 2024, perusahaan memiliki rasio P/E sebesar 57.28.
Riwayat rasio P/E untuk Shenzhen Salubris Pharmaceuticals Co., Ltd. dari 2006 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 49.54 | -42.01% |
| 2025 | 85.43 | 49.15% |
| 2024 | 57.28 | -8.69% |
| 2023 | 62.73 | 10.76% |
| 2022 | 56.64 | 3.66% |
| 2021 | 54.64 | -88.59% |
| 2020 | 478.73 | 1,547.01% |
| 2019 | 29.07 | 108.95% |
| 2018 | 13.91 | -53.00% |
| 2017 | 29.60 | 35.14% |
| 2016 | 21.90 | -11.99% |
| 2015 | 24.89 | 12.31% |
| 2014 | 22.16 | -18.18% |
| 2013 | 27.08 | 2.89% |
| 2012 | 26.32 | 21.29% |
| 2011 | 21.70 | -52.87% |
| 2010 | 46.05 | 21.42% |
| 2009 | 37.93 | -21.12% |
| 2008 | 48.08 | -37.68% |
| 2007 | 77.16 | -44.19% |
| 2006 | 138.24 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 51.86 | 4.67% |
US
|
|
| 32.35 | -34.70% |
FR
|
|
| 33.39 | -32.61% |
JP
|
|
| 58.54 | 18.15% |
US
|
|
| 51.87 | 4.69% |
CH
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.